查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916197

光學成像劑市場按產品類型、成像方式、應用和最終用戶分類－2026-2032年全球預測

Optical Imaging Agent Market by Product Type, Modality, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，光學成像劑市場價值將達到 24.5 億美元，到 2026 年將成長至 25.7 億美元，到 2032 年將達到 38.5 億美元，年複合成長率為 6.66%。

關鍵市場統計數據
基準年 2025 24.5億美元
預計年份：2026年 25.7億美元
預測年份 2032 38.5億美元
複合年成長率 (%) 6.66%

光學成像劑的全面介紹：重點關注技術整合、臨床應用壓力和策略發展需求

光學影像劑領域融合了前沿化學、分子生物學和臨床診斷技術，目前正吸引臨床醫生、研究人員和相關人員的關注，他們尋求的是更高對比、更特異性、更安全的影像解決方案。探針設計、影像儀器和多模態整合技術的進步，正將光學工具的臨床效用從實驗室拓展到術中導航、標靶診斷和非侵入性疾病監測等領域。同時，監管路徑和報銷機制也不斷調整，為臨床應用開闢了新的途徑，同時也提高了證據生成和安全性檢驗的標準。

技術創新、日益成長的監管壓力和營運韌性的融合如何重塑競爭優勢和臨床應用格局？

由於探針化學的進步、日益嚴格的安全性和可重複性監管要求，以及對術中和照護現場成像解決方案需求的不斷成長，光學成像劑領域正經歷著一場變革。奈米顆粒工程和染料化學的創新提高了亮度、光穩定性和靶向特異性，從而實現了以前難以實現的新型成像模式和組合。同時，設備靈敏度和便攜性的提升也為床邊和手術應用創造了機遇，在這些應用中，光學對比度可以直接指導臨床決策。

評估近期美國關稅措施對供應鏈、生產決策和臨床時間表的更廣泛的營運和策略影響

2025年美國關稅的累積影響加劇了依賴進口原料、特殊試劑和精密製造組件的光學成像劑開發相關人員的成本和供應鏈複雜性。關稅相關的成本增加給上游供應商帶來壓力，迫使製造商重新評估其供應商網路，評估近岸外包機會，並根據其合約結構和競爭地位自行承擔或轉嫁成本。這些事態發展凸顯了供應鏈透明度和長期籌資策略的重要性。

詳細的細分揭示了由模態主導的設計選擇、特定應用的證據要求以及最終用戶的採購行為，這些因素共同塑造了商業化策略。

詳細的產品細分有助於明確產品和應用優先級，突顯創新和投資能夠帶來最大臨床和商業性回報的領域。產品類型包括造影劑、螢光染料、發光探針和分子探針。造影劑進一步細分為金奈米顆粒、微氣泡和量子點，而螢光染料則細分為 Alexa Fluor 探針、花菁染料和靛氰綠。這些區分至關重要，因為每種分類在亮度、光穩定性、生物相容性和監管複雜性方面各有優劣。基於成像模式的分類使相關人員能夠開發和部署涵蓋生物發光成像、螢光成像、光學同調斷層掃描和光聲成像的解決方案，而特定成像模式的要求決定了探針的結構、激發和發射參數以及儀器相容性。

區域間在市場接受度、監管複雜性和供應鏈影響方面的差異，需要製定量身定做的市場進入和商業化策略。

區域趨勢對監管預期、支付方環境以及對市場准入和擴大策略至關重要的實施路徑產生了不同的影響。在美洲，臨床研究人員和醫療保健系統優先考慮快速的術中和即時檢測應用，因此對能夠縮短手術時間並提高診斷準確性的工具有著強勁的需求。該地區還擁有複雜的報銷環境以及廣泛的公共和私人研究資金籌措管道。在歐洲、中東和非洲，必須解決不同的法規結構和醫療保健系統能力缺口問題，這需要製定量身定做的監管策略和彈性價格設定模式，以適應不同的採購慣例實踐。

策略聯盟、製造能力和科技差異化如何決定競爭定位和收購吸引力

光學影像劑領域的競爭格局由三者組成：專業創新者、不斷拓展產品線的成熟生命科學公司，以及將利基技術實用化的大學衍生企業。主要企業正致力於將先進的探針化學技術與臨床檢驗項目和可擴展的生產能力相結合，以加快產品進入臨床應用的速度並提升其價值提案。同時，Start-Ups的新創公司往往憑藉其敏捷性和創新性科學脫穎而出，尤其是在靶向奈米顆粒和新一代螢光染料化學等領域。在這些領域，先發優勢能夠帶來長期的臨床差異化。

在複雜的商業環境中，採取切實可行的策略行動，以確保供應彈性、臨床檢驗和可擴展的商業化。

產業領導者應採取一系列切實可行的措施，將創新轉化為持續的市場優勢和臨床影響。首先，早期研發階段應與明確的臨床適應症和相關人員的需求保持一致，確保探針化學成分和模式選擇能夠直接對應目標手術中的可衡量結果。這種一致性可以減少後續監管方面的阻力，並加快與支付方的溝通。其次，應加強供應商多元化和合約保護，以降低進口關稅和原料短缺帶來的風險。此外，應盡可能投資於關鍵部件的冗餘採購和本地化生產，以確保臨床試驗按時完成。

調查方法概述：為確保研究結果的可靠性，我們說明闡述了初步訪談、文獻綜述、法規審查和多方面檢驗。

本研究結合了專家面對面訪談、近期同行評審文獻綜述以及監管指南和公開文件的分析，旨在全面了解光學成像劑的現狀。面對面訪談對象包括化學家、臨床研究人員、法規事務專業人員和採購負責人，以收集從研發到應用整個生命週期的觀點。文獻綜述重點關注探針化學、成像設備和臨床試驗方法的最新進展，以確保技術準確性並與當前實踐相符。

整合技術可行性、證據需求和營運重點，最終確定決定實用化和推廣成功與否的因素。

總而言之，光學影像劑在提高診斷準確性、指導治療性介入以及在臨床診療指南提供可操作的見解方面具有巨大的潛力，但要充分發揮這一潛力，需要化學、臨床證據、監管策略和運營執行等方面的協調配合。奈米顆粒、染料化學和多模態方法的創新拓展了技術能力，但監管機構和支付方的期望也日益提高，要求能夠證明患者獲益並保證可靠的生產。供應鏈中斷和關稅波動帶來了新的營運風險，必須透過採購多元化和策略性投資來增強韌性，從而積極應對這些風險。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依產品類型分類的光學顯影劑市場

  • 造影
    • 金奈米粒子
    • 微氣泡
    • 量子點
  • 螢光染料
    • Alexa Florprobe
    • 花菁染料
    • 靛氰綠
  • 發光探針
  • 分子探針

9. 依影像方式分類的光學成像劑市場

  • 生物發光成像
  • 螢光影像
  • 光學同調斷層掃描
  • 光聲成像

第10章 按應用分類的光學成像劑市場

  • 心血管影像
  • 消化影像
  • 神經影像學
  • 腫瘤影像
    • 乳癌影像學
    • 肺癌影像
    • 前列腺癌影像學

第11章 以最終用戶分類的光學成像劑市場

  • 生技公司
  • 診斷中心
  • 醫院
  • 製藥公司
  • 研究所

第12章 光學成像劑市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 光學造影劑市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國光學成像劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章美國光學造影劑市場

第16章：中國光學造影劑市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Bruker Corporation
  • Canon Inc.
  • Carl Zeiss Meditec AG
  • FUJIFILM Holdings Corporation
  • Hamamatsu Photonics KK
  • Heidelberg Engineering
  • Hologic Inc.
  • Koninklijke Philips NV
  • Leica Microsystems
  • Nikon Corporation
  • Olympus Corporation
  • PerkinElmer, Inc.
  • Siemens Healthineers
  • Topcon Corporation
Product Code: MRR-AE420CB152FB

The Optical Imaging Agent Market was valued at USD 2.45 billion in 2025 and is projected to grow to USD 2.57 billion in 2026, with a CAGR of 6.66%, reaching USD 3.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.45 billion
Estimated Year [2026] USD 2.57 billion
Forecast Year [2032] USD 3.85 billion
CAGR (%) 6.66%

Comprehensive introduction to optical imaging agents emphasizing technological integration, clinical translation pressures, and strategic development imperatives

The field of optical imaging agents sits at the intersection of cutting-edge chemistry, molecular biology, and clinical diagnostics, and it now commands attention from clinicians, researchers, and commercial stakeholders seeking higher-contrast, more specific, and safer imaging solutions. Advances in probe design, imaging instrumentation, and multimodal integration have expanded the clinical utility of optical tools beyond research labs into intraoperative guidance, targeted diagnostics, and noninvasive disease monitoring. Alongside these technical improvements, regulatory pathways and reimbursement frameworks have begun to adapt, creating new routes for clinical adoption while raising the bar for evidence generation and safety validation.

As technical feasibility converges with clinical need, industry participants face a landscape of accelerated innovation and heightened scrutiny. Developers must demonstrate not only the unique performance attributes of contrast agents, fluorescent dyes, luminescent probes, and molecular probes, but also reproducible manufacturing, robust quality control, and clear clinical value propositions tied to patient outcomes. Investors and strategic partners are increasingly focused on end-to-end solutions that integrate reagent chemistry, imaging hardware, and data analytics to deliver actionable results at the point of care. Consequently, early-stage collaboration among chemists, imaging specialists, regulatory experts, and clinicians has become essential to de-risk translation and speed clinical acceptance.

Looking ahead, the introduction of novel nanoparticle formulations and targeted molecular constructs offers promise for improved selectivity and reduced off-target effects, while ongoing work to standardize imaging protocols and performance metrics will support broader adoption. In this context, stakeholders should prioritize clear clinical indications, streamlined regulatory strategies, and manufacturing scalability to ensure that technical innovation translates into meaningful clinical and commercial outcomes.

How converging technological advances, regulatory rigor, and operational resilience are reshaping competitive advantage and clinical adoption dynamics

The landscape for optical imaging agents is undergoing transformative shifts driven by several converging forces: advances in probe chemistry, tighter regulatory emphasis on safety and reproducibility, and increasing demand for intraoperative and point-of-care imaging solutions. Innovations in nanoparticle engineering and dye chemistry have improved brightness, photostability, and target specificity, enabling new imaging modalities and combinations that were previously impractical. At the same time, instrumentation has become more sensitive and portable, creating opportunities for bedside and surgical applications where optical contrast can directly inform clinical decisions.

Simultaneously, regulators and health technology assessors are insisting on higher evidentiary standards, requiring developers to produce robust clinical performance data, harmonized imaging protocols, and clearer demonstrations of patient benefit. This regulatory tightening has pushed companies to invest earlier in clinical validation and to design trials that capture meaningful endpoints. Moreover, payer scrutiny is prompting clearer articulation of cost-effectiveness and value-based use cases, which favors integrated solutions that reduce downstream costs or improve procedural outcomes.

Finally, supply chain resilience and manufacturing quality have become strategic differentiators. As demand for complex formulations grows, organizations that can demonstrate reliable GMP manufacturing, effective scale-up plans, and secure raw material sourcing will command greater trust among clinical partners and procurement teams. Together, these shifts are redefining competitive advantage in the sector, privileging players who can align deep technical capability with clinical evidence generation and operational excellence.

Evaluating the broad operational and strategic consequences of recent US tariff measures on supply chains, manufacturing decisions, and clinical timelines

The cumulative impact of recent United States tariff actions in 2025 has amplified cost and supply-chain complexity for stakeholders dependent on imported raw materials, specialized reagents, and precision manufacturing components used in optical imaging agent development. Tariff-related cost increases have pressured upstream suppliers and compelled manufacturers to reassess supplier networks, evaluate nearshoring possibilities, and absorb or pass on costs depending on contractual structures and competitive positioning. These dynamics have highlighted the importance of supply-chain transparency and long-term sourcing strategies.

In addition to immediate cost implications, tariffs have influenced strategic timelines for product launches and clinical studies. Organizations facing higher input costs have frequently deferred noncritical investments, consolidated vendor relationships to secure volume discounts, or accelerated qualification of alternative suppliers to mitigate exposure. Some firms have explored relocating certain manufacturing steps or analytical testing to jurisdictions with more favorable trade conditions to preserve margin and reduce logistical uncertainty. These adaptations require investment in vendor qualification, regulatory filing updates, and quality oversight to ensure continuity of clinical-grade outputs.

Moreover, tariffs have sharpened conversations around resilience and value chain control among investors and corporate leaders. Firms that can demonstrate diversified sourcing, inventory buffers calibrated to clinical trial schedules, and contractual protections against abrupt cost shifts find themselves better positioned to maintain clinical development timelines. Going forward, tariff impacts will continue to influence where companies invest in manufacturing capacity, how they structure supplier agreements, and the degree to which they prioritize vertical integration versus strategic outsourcing.

In-depth segmentation reveals modality-driven design choices, application-specific evidence needs, and end-user procurement behaviors that dictate commercialization strategies

Deep segmentation clarifies product and application priorities and highlights where innovation and investment will have the highest clinical and commercial payoff. Based on Product Type, the field includes Contrast Agents, Fluorescent Dyes, Luminescent Probes, and Molecular Probes, with Contrast Agents further differentiated into Gold Nanoparticles, Microbubbles, and Quantum Dots and Fluorescent Dyes subdivided into Alexa Fluor Probes, Cyanine Dyes, and Indocyanine Green; these distinctions matter because each class offers different trade-offs in brightness, photostability, biocompatibility, and regulatory complexity. Based on Modality, stakeholders are developing and deploying solutions across Bioluminescence Imaging, Fluorescence Imaging, Optical Coherence Tomography, and Photoacoustic Imaging, and modality-specific requirements dictate probe architecture, excitation and emission parameters, and instrumentation compatibility.

Based on Application, use cases range across Cardiovascular Imaging, Gastrointestinal Imaging, Neurological Imaging, and Oncology Imaging, with Oncology Imaging further examined through Breast Cancer Imaging, Lung Cancer Imaging, and Prostate Cancer Imaging; each clinical domain imposes unique sensitivity, targeting, and safety expectations that influence clinical trial design and commercialization pathways. Based on End User, the principal adopters comprise Biotechnology Companies, Diagnostic Centers, Hospitals, Pharmaceutical Companies, and Research Institutes, and these end-user categories differ in procurement cycles, evidence thresholds, and integration needs. Taken together, this segmentation underscores that a one-size-fits-all approach will not succeed: product development must align chemistry and modality with the specific clinical application and the procurement behavior of targeted end users.

Regional differentiation across adoption, regulatory complexity, and supply-chain exposure demands tailored market entry and commercialization approaches

Regional dynamics shape regulatory expectations, payer environments, and adoption pathways in distinct ways that matter for market entry and scale-up strategies. In the Americas, clinical investigators and health systems emphasize rapid translation into intraoperative and point-of-care use cases, with strong demand for tools that reduce procedural time or improve diagnostic yield; this region also presents complex reimbursement landscapes and robust private and public research funding channels. In Europe, Middle East & Africa, stakeholders navigate diverse regulatory frameworks and heterogeneous health system capacities, which makes tailored regulatory strategies and flexible pricing models essential for adoption across countries with varied procurement practices.

In the Asia-Pacific region, rapid investment in healthcare infrastructure, growing clinical research capacity, and a rising number of centers adopting advanced imaging modalities create opportunities for scale, but these opportunities contend with local manufacturing priorities and variable regulatory timelines. Each region also displays different supply-chain risk profiles and tariff exposure, which influence decisions about where to site manufacturing, how to structure distributor relationships, and the extent to which localization will affect cost and access. Consequently, effective regional strategies combine local regulatory expertise, partnerships with established clinical centers, and adaptable commercialization models that reflect the operational realities of each geography.

How strategic partnerships, manufacturing readiness, and scientific differentiation determine competitive positioning and acquisition appeal

Competitive dynamics in the optical imaging agent space reflect a mix of specialist innovators, established life sciences firms expanding their portfolios, and academic spinouts translating niche technologies. Leading organizations invest in integrated capabilities that combine advanced probe chemistry with clinical validation programs and scalable manufacturing to shorten time-to-clinic and strengthen value propositions. At the same time, nimble startups often outperform on agility and novel science, particularly in areas such as targeted nanoparticles and next-generation fluorescent dye chemistries where first-mover scientific advantage can create long-term clinical differentiation.

Partnerships and strategic alliances play a central role in advancing complex programs, with many companies choosing to collaborate with instrument manufacturers, clinical research networks, and contract manufacturers to accelerate development and de-risk scale-up. Licensing deals and co-development arrangements enable diffusion of proprietary chemistries into broader platforms while preserving route-to-market benefits for originators. In parallel, contract research and manufacturing organizations that can meet stringent quality standards and support method transfer have become critical enablers of commercialization. Investors and acquirers are evaluating company portfolios through dual lenses of technical uniqueness and operational readiness, favoring entities that present clear clinical plans, validated analytical methods, and defensible IP.

Practical strategic actions for leaders to secure supply resilience, clinical validation, and scalable commercialization in a complex operating environment

Industry leaders should pursue a pragmatic set of actions to translate innovation into durable market advantage and clinical impact. First, align early-stage development with clear clinical indications and stakeholder needs so that probe chemistry and modality selection directly address measurable outcomes in targeted procedures. This alignment reduces downstream regulatory friction and accelerates payer conversations. Second, strengthen supplier diversification and contractual protections to reduce exposure to import tariffs and raw material shortages, and where feasible invest in redundant sourcing or localized manufacturing for critical components to safeguard clinical timelines.

Third, embed evidence-generation strategies into product roadmaps, prioritizing trials and real-world data collection that demonstrate patient outcomes, workflow efficiency, and economic value. Fourth, pursue collaborative pathways with instrumentation partners and clinical sites to co-develop end-to-end solutions that simplify adoption for hospitals and diagnostic centers. Fifth, maintain rigorous quality systems and early GMP planning to ensure that scale-up does not introduce regulatory setbacks. Finally, adopt flexible commercial models-such as bundled offerings, outcome-linked pricing, or service-enabled deployments-that respond to diverse end-user procurement preferences and support faster uptake. By executing these measures, leaders can convert technical promise into reproducible clinical benefit and sustainable commercial performance.

Methodological summary detailing primary interviews, literature synthesis, regulatory review, and multi-source triangulation to ensure robust findings

This research synthesizes primary interviews with domain experts, a review of recent peer-reviewed literature, and an analysis of regulatory guidance and public filings to develop a comprehensive view of the optical imaging agent landscape. Primary interviews included chemists, clinical investigators, regulatory affairs specialists, and procurement professionals to capture perspectives across the development and adoption lifecycle. The literature review emphasized recent advances in probe chemistry, imaging instrumentation, and clinical trial methodologies, ensuring technical accuracy and alignment with contemporary practice.

Analytical methods combined qualitative synthesis with cross-case comparison to identify recurrent themes in technology performance, clinical evidence generation, and operational readiness. Regulatory analysis focused on guidance documents, approval pathways for companion diagnostics and imaging agents, and emerging requirements for clinical validation. Supply-chain and tariff impact assessments relied on documented trade actions, reported vendor adjustments, and observed shifts in procurement strategies to produce an operationally grounded view of risk and adaptation. Throughout, methodological rigor included triangulation of multiple data sources and validation of key findings with subject-matter experts to ensure relevance and reliability.

Concluding synthesis of technological promise, evidence imperatives, and operational priorities that will determine successful translation and adoption

In conclusion, optical imaging agents present compelling opportunities to improve diagnostic precision, guide interventions, and deliver actionable insights at the point of care, but realizing that potential requires coordinated attention to chemistry, clinical evidence, regulatory strategy, and operational execution. Innovations in nanoparticles, dye chemistries, and multimodal approaches have expanded technical capabilities, while regulatory and payer expectations increasingly demand demonstrable patient benefit and reliable manufacturing. Supply-chain disruptions and tariff shifts have introduced new operational risks that must be actively managed through diversified sourcing and strategic investments in resilience.

Successful organizations will therefore integrate early clinical alignment with robust quality systems and adaptable commercial models. Strategic partnerships across instrumentation providers, clinical networks, and manufacturing specialists will accelerate adoption and de-risk scale-up. Meanwhile, regionally tailored approaches that reflect regulatory, reimbursement, and procurement realities will be essential for global impact. By prioritizing evidence generation, supply resiliency, and close collaboration with clinical end users, developers can translate scientific advances into meaningful clinical improvements and sustainable business models.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Optical Imaging Agent Market, by Product Type

  • 8.1. Contrast Agents
    • 8.1.1. Gold Nanoparticles
    • 8.1.2. Microbubbles
    • 8.1.3. Quantum Dots
  • 8.2. Fluorescent Dyes
    • 8.2.1. Alexa Fluor Probes
    • 8.2.2. Cyanine Dyes
    • 8.2.3. Indocyanine Green
  • 8.3. Luminescent Probes
  • 8.4. Molecular Probes

9. Optical Imaging Agent Market, by Modality

  • 9.1. Bioluminescence Imaging
  • 9.2. Fluorescence Imaging
  • 9.3. Optical Coherence Tomography
  • 9.4. Photoacoustic Imaging

10. Optical Imaging Agent Market, by Application

  • 10.1. Cardiovascular Imaging
  • 10.2. Gastrointestinal Imaging
  • 10.3. Neurological Imaging
  • 10.4. Oncology Imaging
    • 10.4.1. Breast Cancer Imaging
    • 10.4.2. Lung Cancer Imaging
    • 10.4.3. Prostate Cancer Imaging

11. Optical Imaging Agent Market, by End User

  • 11.1. Biotechnology Companies
  • 11.2. Diagnostic Centers
  • 11.3. Hospitals
  • 11.4. Pharmaceutical Companies
  • 11.5. Research Institutes

12. Optical Imaging Agent Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Optical Imaging Agent Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Optical Imaging Agent Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Optical Imaging Agent Market

16. China Optical Imaging Agent Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Bruker Corporation
  • 17.7. Canon Inc.
  • 17.8. Carl Zeiss Meditec AG
  • 17.9. FUJIFILM Holdings Corporation
  • 17.10. Hamamatsu Photonics K.K.
  • 17.11. Heidelberg Engineering
  • 17.12. Hologic Inc.
  • 17.13. Koninklijke Philips N.V.
  • 17.14. Leica Microsystems
  • 17.15. Nikon Corporation
  • 17.16. Olympus Corporation
  • 17.17. PerkinElmer, Inc.
  • 17.18. Siemens Healthineers
  • 17.19. Topcon Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OPTICAL IMAGING AGENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OPTICAL IMAGING AGENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA OPTICAL IMAGING AGENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GOLD NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GOLD NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GOLD NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MICROBUBBLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MICROBUBBLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MICROBUBBLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY QUANTUM DOTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY QUANTUM DOTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY QUANTUM DOTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ALEXA FLUOR PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ALEXA FLUOR PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ALEXA FLUOR PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CYANINE DYES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CYANINE DYES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CYANINE DYES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY INDOCYANINE GREEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY INDOCYANINE GREEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY INDOCYANINE GREEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY LUMINESCENT PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY LUMINESCENT PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY LUMINESCENT PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MOLECULAR PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MOLECULAR PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MOLECULAR PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BIOLUMINESCENCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PHOTOACOUSTIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PHOTOACOUSTIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PHOTOACOUSTIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY CARDIOVASCULAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GASTROINTESTINAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY NEUROLOGICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY NEUROLOGICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY NEUROLOGICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BREAST CANCER IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BREAST CANCER IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BREAST CANCER IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY LUNG CANCER IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY LUNG CANCER IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY LUNG CANCER IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PROSTATE CANCER IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PROSTATE CANCER IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PROSTATE CANCER IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 164. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 165. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 166. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 168. GCC OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 189. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 190. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 192. G7 OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 197. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 198. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 200. NATO OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL OPTICAL IMAGING AGENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA OPTICAL IMAGING AGENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY CONTRAST AGENTS, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY FLUORESCENT DYES, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY ONCOLOGY IMAGING, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA OPTICAL IMAGING AGENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)